Laboratorios Farmaceuticos Rovi, S.A.
LABFF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $4 | $3 | $3 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $5 | $3 | $2 | $3 |
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | -7.9% | 1.4% | 26.1% | – |
| Gross Profit | $0 | $0 | $1 | $0 |
| % Margin | 61.2% | 58.3% | 62.7% | 58.6% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 26.1% | 28.7% | 33.2% | 30.3% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 17.9% | 20.5% | 24.4% | 23.6% |
| EPS Diluted | 2.67 | 3.2 | 3.73 | 2.76 |
| % Growth | -16.6% | -14.2% | 35.1% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |